Navigation Links
Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Date:5/12/2011

SAN FRANCISCO, May 12, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that key data from its Phase 2 randomized clinical study in advanced liver cancer patients, along with data from other JX-594 clinical trials, will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 18-21, 2011, in Seattle, Washington.  These data, evaluating multi-dose administration of JX-594 in U.S., Korean and Canadian patients with advanced liver cancer, were selected for an oral presentation at the ASGCT Presidential Symposium. Additionally, these data have been chosen for inclusion in ASGCT's Media Event to be held during the annual meeting.

The presentation details are as follows:

Abstract Title: "Demonstration of Safety and Antitumoral Activity of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, Following Intravenous Infusion and/or Intratumoral Injections in Patients with Refractory Metastatic Cancers" (Abstract #50)

Presenter: David H. Kirn, M.D., president and chief executive officer of Jennerex

Session: Presidential Symposium, May 19, 2011, 9:05 a.m. PDT

About JX-594

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
2. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
3. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
4. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
5. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Closes $5 Million First Tranche of Series C Financing
8. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
9. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
10. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
11. Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... SAN DIEGO , May 24, 2013 ... a  company using proprietary taste science technologies to discover, ... David Linemeyer , Ph.D., the Company,s ... , Vice President, Investor Relations & Corporate Communications, will ... Friday, May 31, at 10:25 a.m. Eastern Time (7:25 ...
(Date:5/24/2013)... Toronto, Canada (PRWEB) May 24, 2013 ... selective barriers, and uptake or efflux transporters at the ... may be related to unbound fractions in the tissue ... understanding of these disposition challenges is required to guide ... and to identify any species-dependent variables that may impact ...
(Date:5/24/2013)... 24, 2013 Vestiage, Inc. (stock ... focused on science-based research and development, sales and ... and nutraceuticals, announced today that it is awarding ... the sale of Reluma Skin Illuminating Facial Care. ... application by sending an email to info(at)vestiageinc(dot)com and ...
(Date:5/23/2013)... England , May 24, 2013 ... Mundipharma angefertigt – Bei der ... , 91 % der Teilnehmer einer groß ... nur 20 % laut GINA [*] -Definition [1] ... dass Menschen mit Asthma generell einer von vier Denkweisen ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
... Watch out, iPod and Sirius Radio; here comes Motorola. The company ... or commercial-free Internet radio through your cell phone. You can play ... your car or on your home stereo and transition from ... WTN's Mike Klein traveled to Arizona to get the scoop. Original ...
... merged with STI Knowledge, an Atlanta-based provider of ... BPO company with offices in Norristown, Pennsylvania; Scottsdale, ... off from its parent Symphony Corp. , ,Symphony ... BPO services, with a particular expertise in the ...
... and Intermountain Health Care (IHC) have announced ... would accelerate the adoption of electronic health records among ... the annual Healthcare Information and Management Systems Society (HIMSS) ... take the clinical knowledge that IHC has gathered over ...
Cached Biology Technology:GE and Intermountain want to streamline nationwide patient data 2
(Date:5/23/2013)... the natural history museums of the world are billions ... beetles to flowers, mushrooms and grasses, all stacked, stored ... rich and diverse collections could be critical to understanding ... of a growing human footprint if only the ... brought to life with the help of a team ...
(Date:5/23/2013)... Publishing in Neuron , the team reveal the ... in work funded by the Wellcome Trust and BBSRC. ... external stimuli we improve our perceptual abilities. While these ... they can also affect the fidelity of that response. ... Visual Neuroscience explains: "When you communicate with others, you ...
(Date:5/22/2013)... 2013 U.S. Forest Service scientists are part of ... from the TKF Foundation, will examine how collaborative planning ... recover from tragedy. , The TKF Foundation announced today ... selected for grant funding. In addition to research on ... recovery and resiliency, the 3-year, $585,000 grant will contribute ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... the dynamics of a deadly disease that is wiping ... today in the Proceedings of the National Academy ... severity of the disease among individuals -- determines whether ... fungal disease called Chytridiomycosis . The research identifies ...
... been a hard winter for Monarch butterflies, according to Chip ... Taylor said that low temperatures, storms and habitat destruction have ... "I spend a lot of time fretting over the status ... or data that will help me understand the past as ...
... at the University of Michigan Comprehensive Cancer Center ... neck cancer to avoid treating critical structures that ... these principles and techniques treated the cancer effectively ... researchers applied highly conformal, intensity-modulated radiation therapy and ...
Cached Biology News:New insights into how deadly amphibian disease spreads and kills 2New insights into how deadly amphibian disease spreads and kills 3New insights into how deadly amphibian disease spreads and kills 4As monarch butterflies journey north, gardeners can help protect species, researcher says 2U-M study achieves reduced side effects in head and neck cancer treatment 2
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
... Signets FAST RED Chromogen System consists of ... RED reacts in the presence of alkaline ... background noise. The FAST RED System ... ,The System Contains: , , Vial A: ...
The BioLogic Maximizer mixer is for use with the Maximizer valve system. The mixer improves gradient quality by mixing the output of the BioLogic DuoFlow workstation pumps....
Biology Products: